1. The 5-year disease-free survival was 80.3% in the exercise group and 73.9% in the education group, with an overall...

1. Median overall survival was 13.6 months in the tarlatamab group and 8.3 months in the chemotherapy group, with HR...

1. Event-free survival at 24 months was 67.4% in the durvalumab group and 58.5% in the placebo group, with HR...

1. ctDNA detection was found to have a relapse HR of 2.91 in the placebo and HR 2.98 in the...

1. Recurrent VTE occurred in 2.1% in the reduced-dose group and 2.8% in the full-dose group, with HR 0.76 (was...

1 .The objective response rate was 88.8% for TKI-naïve patients and 55.8% for TKI-pretreated patients. 2. Most common adverse events...

1. A total of 2% of the eligible population was diagnosed with lung cancer after a positive screen on baseline...

1. Overall survival at 2 years was 74% for active surveillance and 71% for standard surgery. 2. Median disease-free survival...

1. Cooling was found to have a relative risk reduction of 42% and compression had a relative risk reduction of...

1. Intracranial objective response rate was 51% with ipilimumab plus nivolumab and 20% with nivolumab alone. 2. Treatment-related grade 3...